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Aliskiren, an Oral Renin Inhibitor, Provides
Dose-Dependent Efficacy and Sustained 24-Hour
Blood Pressure Control in Patients With Hypertension
Byung-Hee Oh, MD, PHD, FACC,* Jerry Mitchell, MD, PHD,†‡ James R. Herron, MD,§
Jenny Chung, PHARMD, Mahmudul Khan, PHD, Deborah L. Keefe, MD, MPH, FACC
Seoul, Korea; Houston, Texas; Chicago, Illinois; and East Hanover, New Jersey
Objectives This dose-ranging study evaluated the antihypertensive efficacy and tolerability of aliskiren in patients with mild-
to-moderate hypertension.
Background Low blood pressure (BP) control rates among patients with hypertension indicate a need for improved treatment
options. This study investigates aliskiren, the first in a new antihypertensive class called renin inhibitors.
Methods Patients with mean sitting diastolic BP 95 to 109 mm Hg were randomized to aliskiren 150, 300, or 600 mg or
placebo once daily for 8 weeks. Patients completing this treatment phase entered a 2-week treatment-free with-
drawal period. Office BP was recorded at baseline, weeks 2, 4, 6, and 8 of treatment, and 4 days and 2 weeks
after cessation of treatment. A subgroup of patients underwent ambulatory BP monitoring.
Results In total, 672 patients were randomized to treatment. After 8 weeks, aliskiren 150, 300, and 600 mg signifi-
cantly reduced mean sitting BP (systolic/diastolic) by 13.0/10.3, 14.7/11.1, and 15.8/12.5 mm Hg, respec-
tively, versus 3.8/4.9 mm Hg with placebo (all p  0.0001 for systolic and diastolic BP). The BP-lowering effect
of aliskiren persisted for up to 2 weeks after treatment withdrawal. Aliskiren significantly reduced mean 24-h
ambulatory BP (p  0.0001 vs. placebo with all doses) exhibiting smooth, sustained effects and high trough-to-
peak ratios. Aliskiren was well tolerated; overall adverse event rates were 40.1%, 46.7%, and 52.4% with
aliskiren 150, 300, and 600 mg, respectively, and 43.0% with placebo. Few patients discontinued treatment
due to adverse events.
Conclusions Aliskiren provides significant antihypertensive efficacy in patients with hypertension, with no rebound effects on
blood pressure after treatment withdrawal. (J Am Coll Cardiol 2007;49:1157–63) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.032t
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tliskiren is the first in a new class of orally effective renin
nhibitors and is a potent inhibitor of human renin (1).
liskiren has a half-life of approximately 40 h (2,3), making
t suitable for once-daily dosing, with less potential for loss
f efficacy between doses than shorter-acting agents. Con-
inuous 24-h blood pressure (BP) control throughout the
osing period is clinically important, as it can reduce BP
ariability that may be suboptimally controlled in other drug
lasses (4–6).
rom the *Seoul National University Hospital, Seoul, Korea; †Texas Center for Drug
evelopment, Houston, Texas; ‡Baylor College of Medicine, Houston, Texas;
James R. Herron, MD, Ltd., Chicago, Illinois; and Novartis Pharmaceuticals
orporation, East Hanover, New Jersey. This study was supported by Novartis. Drs.
eefe, Chung, and Khan are all full-time employees of Novartis and are eligible for
ovartis stock or stock options.a
Manuscript received June 27, 2006; revised manuscript received October 19, 2006,
ccepted November 6, 2006.Previous clinical trials of aliskiren in patients with mild-
o-moderate hypertension have demonstrated BP lowering
t least comparable with the angiotensin receptor blockers
ARBs) irbesartan and losartan (7,8), with placebo-like
olerability (7). Consistent with its mechanism of action,
liskiren has also been shown to reduce plasma renin activity
PRA) from baseline, both in hypertensive patients and in
ealthy volunteers (9,10).
See page 1164
In this dose-ranging study, we further evaluated the
ntihypertensive efficacy of aliskiren at doses of 150 to 600
g in patients with mild-to-moderate essential hyperten-
ion. We also assessed safety and tolerability, and the effects
f aliskiren on PRA and renin concentration (RC). Moni-
oring of BP, PRA, and RC continued after cessation of
liskiren treatment to detect any potential rebound effect.
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Participants. Men and women
age 18 years with mild-to-
moderate essential hypertension
(mean sitting diastolic blood pres-
sure [msDBP] 95 and 110
mm Hg) were recruited at 68 cen-
ters internationally.
Subjects were excluded from the
study if they had severe hyperten-
sion (msDBP 110 mm Hg) or
secondary hypertension; a history
of serious cardiac or cerebrovascu-
lar disease; type 1 or 2 diabetes mel-
litus with poor glycemic control
(glycosylated hemoglobin 9%); or
any condition that may affect the
absorption, distribution, metabo-
lism, or excretion of the study drug.
All patients provided written
nformed consent. The study design was approved by the
ppropriate local ethical review boards and conducted in
ccordance with the principles of the 1996 Declaration of
elsinki of the World Medical Association.
tudy design. This was a randomized, double-blind,
lacebo-controlled, parallel-group, multicenter study. After
ithdrawal of antihypertensive therapy during a 2-week
ashout period and a screening assessment, patients entered
2- to 4-week single-blind placebo run-in period, at the
nd of which BP eligibility was confirmed and baseline BP
alues established.
Patients who satisfied the inclusion criteria were randomized
o receive once-daily, double-blind treatment with aliskiren,
50, 300, or 600 mg, or placebo for 8 weeks. Patients were
nstructed to take study medication at approximately 8 AM
aily, or after BP assessments on the morning of clinic visits.
atients completing the 8-week, double-blind treatment pe-
iod entered a 2-week, treatment-free withdrawal period.
ollow-up visits were conducted at weeks 2, 4, 6, and 8, and 4
ays and 2 weeks after withdrawal.
tudy objectives. The primary objective of the study was to
valuate reductions in msDBP with aliskiren 150, 300, or
00 mg compared with placebo. Secondary objectives were
o assess reductions in mean sitting systolic blood pressure
msSBP); the dose-response relationship; 24-h ambulatory
P monitoring (ABPM) profiles and trough-to-peak ratios
or aliskiren; the proportion of patients achieving a successful
reatment response (defined as msDBP 90 mm Hg and/or
10 mm Hg reduction from baseline) or BP control (BP
140/90 mm Hg); the effects of aliskiren on PRA and RC;
he safety and tolerability of aliskiren 150 to 600 mg; and the
ffect of treatment withdrawal on BP, PRA, and RC.
ffice BP measurements. Blood pressure was measured
sing a standard, calibrated sphygmomanometer in accor-
Abbreviations
and Acronyms
ABPM  ambulatory blood
pressure monitoring
AE  adverse event
ARB  angiotensin
receptor blocker
BP  blood pressure
ITT  intent-to-treat
LSM  least squares mean
maDBP/maSBP 
mean ambulatory diastolic/
systolic blood pressure
msDBP/msSBP  mean
sitting diastolic/systolic
blood pressure
PRA  plasma renin
activity
RC  renin concentrationance with the American Heart Association Committee on plood Pressure Determination (11). Sitting BP was mea-
ured at trough (24  3 h after last dose) in the arm that
ave the highest reading at the first study visit. Three BP
easurements taken at 1- to 2-min intervals were used to
alculate msDBP and msSBP for that visit.
mbulatory BP monitoring. A subgroup of patients un-
erwent 24-h ABPM before the first dose at randomization
nd after administration of the last dose of study medication
n the double-blind treatment period. The ABPM device
as calibrated to within 7 mm Hg of the mean of 3 BP
easurements taken using a standard sphygmomanometer.
RA and RC measurements. Plasma renin activity (radio-
mmunoassay of generated Ang I, DiaSorin kit, Saluggia,
taly) and RC (immunochemiluminescence, Nichols Direct
enin assay, San Clemente, California) were measured from
lasma samples taken from a subset of patients at selected
reatment centers at baseline and week 8 of the treatment
eriod, and 4 days and 2 weeks after withdrawal in patients
ompleting 8 weeks’ treatment.
afety and tolerability assessments. The safety population
omprised all randomized patients who received at least 1
ose of study medication in the double-blind treatment
eriod. Safety assessments included monitoring and record-
ng all adverse events (AEs) and serious AEs (and possible
elationship to study drug), laboratory tests, electrocardio-
rams, and vital signs. Fisher exact test was used to compare
ates of individual AEs across treatment groups.
tatistical methods. A sample size sufficient for at least 138
atients per group to complete 8 weeks’ treatment was selected
o achieve 90% power to detect a statistically significant
ifference in msDBP of at least 3.5 mm Hg between aliskiren
nd placebo, assuming an SD of 8 mm Hg.
Efficacy analyses were performed on the intent-to-treat
ITT) population (randomized patients with efficacy mea-
urements at baseline and at least 1 measurement in the
ouble-blind treatment period). Analyses were performed at
eek 8 end point (last observation carried forward for
atients discontinuing before this time).
Changes from baseline in msDBP (or msSBP) were
ssessed using an analysis of covariance (ANCOVA) model
ith treatment and region as factors and baseline msDBP
or msSBP) as a covariate. To assess the reductions in BP
ith aliskiren doses (150, 300, and 600 mg) compared with
lacebo, pairwise comparisons were performed with pla-
ebo, with Dunnett’s procedure (12,13) used to adjust for
he multiple comparisons of the aliskiren doses versus
lacebo. Changes in BP in the subgroups of Caucasian and
lack patients were compared by ANCOVA using the
unnett-Hsu test to adjust for multiple comparisons.
The relationship between aliskiren dose and change from
aseline in msDBP was assessed based on first-order and
econd-order regression analyses with dose as the predictor
ariable (including placebo as 0-mg dose). Linear and
uadratic coefficients were tested versus 0 at the 2-sided 5%
ignificance level. The lack-of-fit test for the model was
erformed at the 10% significance level.
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March 20, 2007:1157–63 Dose-Related BP Lowering by AliskirenResponder and BP control rates at each aliskiren dose
ere compared with placebo using a logistic regression
odel with treatment and region as factors and baseline
sDBP as a covariate.
Hourly mean ambulatory diastolic and systolic BP (maDBP
nd maSBP) were calculated as the mean of the readings taken
uring the corresponding post-dosing hour. Mean 24-h, day-
ime (between 6 AM and 10 PM) and nighttime (between 10 PM
nd 6 AM) maDBP and maSBP were also calculated.
Treatment effects on mean 24-h maDBP and maSBP were
nalyzed using a 2-way repeated-measures ANCOVA model
ith treatment, region, and post-dosing hour as factors and
aseline mean 24-h maDBP and maSBP as covariates. Treat-
ent by post-dosing-hour interaction was also included in the
odel. A similar ANCOVA model was used to analyze
hanges in mean daytime and nighttime maDBP and maSBP.
atios between placebo-subtracted least squares mean (LSM)
alues at trough (post-dosing hour 24) and each of post-dosing
ours 1 to 23 were calculated for each aliskiren dose. The
mallest ratio was taken as the trough-to-peak ratio.
esults
articipants. Of the 833 patients enrolled in the study, 672
Figure 1 Patient Flow
*One patient was randomized to aliskiren 300 mg but did not have any baseline or poere randomized to double-blind treatment and comprised nhe safety population. The ITT population consisted of 662
atients; of these, 608 completed 8 weeks’ double-blind
reatment and entered the withdrawal period (Fig. 1).
The randomized population was predominantly male
61.6%) and Caucasian (61.3%), with a mean age of 53
ears. Treatment groups were well matched for demograph-
cs and baseline characteristics, although there was a slightly
igher incidence of metabolic syndrome in the aliskiren 150
g group than in other groups (Table 1).
fficacy. Aliskiren was significantly superior to placebo in
owering msDBP and msSBP (p  0.0001; ANCOVA with
unnett’s procedure to correct for multiple comparisons).
airwise comparisons revealed that all doses (150 to 600 mg)
ielded significantly greater reductions in both msDBP and
sSBP than placebo (all p  0.0001). After 8 weeks’ treat-
ent, aliskiren 150, 300, and 600 mg reduced msDBP by
LSM  SEM) 10.3  0.63, 11.1  0.64, and 12.5  0.64
m Hg, respectively, versus 4.9 0.64 mm Hg with placebo.
Corresponding values for msSBP were 13.0  1.01,
4.7  1.02, and 15.8  1.02 mm Hg, respectively, versus
.8  1.02 mm Hg with placebo (Fig. 2A).
Notable BP lowering (approximately 70% to 80% of
aximal reductions) was apparent by week 2; maximal or
eline evaluations and was not included in numbers completing or discontinuing.st-basear maximal reductions were achieved by week 4 and were
s
m
t
t
r
q
m
p
6
3
(
0
a
w
t
0
r
a
H
c
r
W
8
p
t
2
2
b
2
r
t
a
w
2
w
(
p
H
S
2
1
(
v
n
1
w
0
i
n
6
H
1
a
m
t
t
l
a
t
w
P
m
w
A
b
7
f
t
a
ssure;
1160 Oh et al. JACC Vol. 49, No. 11, 2007
Dose-Related BP Lowering by Aliskiren March 20, 2007:1157–63ustained throughout the remainder of the 8-week treat-
ent period (Fig. 2B). Although aliskiren reduced msDBP
o a greater extent with increasing dosage, the increase in
he magnitude of effect was shallow, and the dose-response
elationship was not consistent with either a linear or
uadratic model (p  0.05 for lack-of-fit).
The proportion of patients achieving a successful treat-
ent response with aliskiren was significantly higher than
lacebo (p  0.0001) for all 3 doses (59.3%, 63.3%, and
9.3%, with aliskiren 150, 300, and 600 mg, respectively, vs.
6.2% with placebo). Blood pressure control rates
BP 140/90 mm Hg) were also significantly higher (p 
.001) with aliskiren 150, 300, and 600 mg (35.9%, 41.6%,
nd 46.4%, respectively) than with placebo (20.3%).
The magnitude of BP reductions with aliskiren treatment
as significantly smaller in black patients (n  79) relative
o Caucasian patients (n  408) for both msDBP (p 
.0001) and msSBP (p  0.0004). Least-squares mean BP
eductions (SBP/DBP) at end point with aliskiren 150, 300,
nd 600 mg were 13.1/11.6, 13.9/11.2, and 14.7/12.5 mm
g, respectively, in Caucasians (placebo 1.6/5.5 mm Hg)
ompared with 8.5/4.8, 11.2/7.5, and 9.6/8.4 mm Hg,
espectively, in black patients (placebo 1.5/2.8 mm Hg).
ithdrawal effect on BP. A total of 608 patients completed
weeks’ treatment and were eligible to enter the withdrawal
eriod. No rebound increase in BP occurred after cessation of
reatment. Blood pressure increased only gradually during the
-week withdrawal period and did not return to baseline (Fig.
B); msDBP remained 6.8, 6.9, and 8.7 mm Hg below
aseline, and msSBP 7.9, 7.1, and 10.0 mm Hg below baseline
weeks after stopping aliskiren 150, 300, and 600 mg,
espectively. Blood pressure remained lower in aliskiren groups
han the placebo group, in which msDBP and msSBP were 5.3
nd 4.9 mm Hg below baseline, respectively, at the end of the
ithdrawal period (Fig. 2B).
4-h ABPM. In the subgroup of 216 patients who under-
Patient Demographics and Baseline Characteris
Table 1 Patient Demographics and Baseline
Placebo
(n  165)
15
(n
Gender (% male) 63.0
Race (% Caucasian) 58.2
Mean age (yrs) 53
Obese (BMI 30 kg/m2) (%) 38.8
Diabetes (%) 5.5
Metabolic syndrome* (%) 40.0
msDBP (mm Hg) 99.4
msSBP (mm Hg) 151.0 1
PRA† (ng/ml/h) 0.62
RC† (U/ml) 8.53
*Indicated by at least 3 of the following 5 features: 1) waist circumf
1.69 mmol/l; 3) high-density lipoprotein cholesterol40 mg/dl or 1
130/85 mm Hg; 5) fasting glucose 110 mg/dl or 6.1 mmol/l.
[PRA]/265 for renin concentration [RC]).
BMI  body mass index; msDBP  mean sitting diastolic blood preent ABPM, aliskiren 150, 300, and 600 mg significantly bp  0.0001) reduced mean 24-h maDBP relative to
lacebo by 8.16  0.92, 7.56  0.90, and 9.04  0.91 mm
g, respectively (placebo-subtracted reductions) (Fig. 2C).
imilarly, significant (p  0.0001 vs. placebo) reductions in
4-h maSBP were observed for aliskiren 150 (11.39 
.31 mm Hg), 300 (10.52  1.29 mm Hg), and 600 mg
11.67  1.29 mm Hg).
Significant reductions in ambulatory BP with aliskiren
ersus placebo were apparent during both daytime and
ighttime. Mean daytime maDBP was reduced by 6.55 
.16, 6.24  1.13, and 8.16  1.14 mm Hg from baseline
ith aliskiren 150, 300, and 600 mg, respectively (all p 
.0001 compared with an increase of 1.25  1.16 mm Hg
n the placebo group). Corresponding reductions in mean
ighttime maDBP were 6.94  1.16, 4.77  1.14, and
.31  1.14 mm Hg with aliskiren 150, 300, and 600 mm
g, respectively (all p  0.0001 vs. an increase of 2.16 
.16 mm Hg in the placebo group). Similarly, all doses of
liskiren significantly reduced daytime and nighttime
aSBP (all p  0.0001 vs. placebo).
Reductions in maDBP and maSBP were consistent across
he 24-h dosing interval with all aliskiren doses. Even
oward the end of the dosing period, consistent maDBP
owering versus baseline and clear separation between each
liskiren dose and placebo were maintained (Fig. 2C). The
rough-to-peak ratios for aliskiren 150, 300, and 600 mg
ere 0.64, 0.98, and 0.86, respectively.
RA and RC. Plasma renin activity and RC measure-
ents at baseline and week 8 of double-blind treatment
ere available for a subset of approximately 270 patients.
liskiren 150, 300, and 600 mg reduced PRA from
aseline (geometric mean change) by 79.5%, 81.1%, and
5.0%, respectively, whereas PRA increased by 19.5%
rom baseline in the placebo group. In patients entering
he withdrawal period (n  240), PRA increased gradu-
lly after withdrawal of aliskiren, but had not returned to
Safety Population, n  672)
racteristics (Safety Population, n  672)
Aliskiren
)
300 mg
(n  169)
600 mg
(n  166)
Overall
(n  672)
62.7 58.4 61.6
63.3 62.7 61.3
54 53 53
34.9 39.8 37.1
7.7 7.2 7.0
40.2 42.8 42.7
99.7 99.4 99.6
153.1 151.9 152.1
0.93 0.58 0.73
12.68 8.21 9.89
102 cm (men)/88 cm (women); 2) triglycerides 150 mg/dl or
ol/l (men)/50 mg/dl or 1.29 mmol/l (women); 4) blood pressure
etric means (subgroup analysis; n  264 for plasma renin activity
msSBP  mean sitting systolic blood pressure.tics (
Cha
0 mg
 172
62.2
61.0
52
34.9
7.6
47.7
99.7
52.2
0.88
10.75
erence
.04 mm
†Geomaseline after 2 weeks; PRA remained 49.6%, 64.7%, and
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g groups, respectively.
The 8 weeks’ aliskiren treatment resulted in dose-
ependent increases from baseline in RC (51.5%, 101.6%,
nd 228.5% for 150, 300, and 600 mg, respectively), while
C was almost unchanged in the placebo group. Renin
oncentration gradually returned toward baseline after with-
rawal of aliskiren, but remained somewhat elevated 2
eeks after treatment discontinuation, particularly in pa-
ients who had received aliskiren 600 mg for 8 weeks (8.6%,
4.3%, and 72.9% above baseline for aliskiren 150, 300, and
00 mg groups, respectively).
afety and tolerability. Aliskiren (150 to 600 mg) was
ell tolerated. During the double-blind treatment period,
he proportion of patients experiencing AEs with
liskiren 150, 300, and 600 mg was 40.1%, 46.7%, and
2.4%, respectively, compared with 43.0% in the placebo
Figure 2 Effects of Aliskiren, 150 to 600 mg, and Placebo on B
(A) Change from baseline to week 8 in mean sitting diastolic blood pressure (msD
bars  msDBP. (B) Changes in msDBP during double-blind treatment and withdraw
(DBP) over 24 h.roup (Table 2). iThe most frequent AEs overall were headache (5.4% to
.7% across treatment groups) and nasopharyngitis (1.8% to
.1%) (Table 2). The slightly higher overall AE rate in the
liskiren 600 mg group was largely accounted for by a
ignificantly higher incidence of diarrhea compared with other
roups (11.4% vs. 1.2% to 1.8%; p  0.0001) (Table 2).
owever, only 1 patient in this group discontinued due to
iarrhea. Overall, there were few discontinuations due to
Es, and the frequency was lower in the active treatment
roups (0.6% to 1.8%) than with placebo (3.6%).
There were 4 serious AEs (1, 2, and 1 in the aliskiren
50, 300, and 600 mg groups, respectively), but none were
uspected to be treatment related. No deaths occurred
uring the study.
During the drug withdrawal period, the most frequent
Es were headache (3.0%) and nasopharyngitis (1.2%). No
atients in any of the aliskiren treatment groups had an AE
Pressure in Patients With Mild-to-Moderate Hypertension
nd mean sitting systolic blood pressure (msSBP). Closed bars  msSBP; open
riod. (C) Change from baseline in mean ambulatory diastolic blood pressurelood
BP) a
al penvolving elevated BP during this period. One patient
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Dose-Related BP Lowering by Aliskiren March 20, 2007:1157–630.6%) had a serious AE (venous occlusion) during the
ithdrawal period.
iscussion
his study demonstrated the antihypertensive efficacy of
nce-daily aliskiren 150 to 600 mg in patients with mild-
o-moderate hypertension, with BP reductions maintained
hroughout the 24-h dosing period. Overall, the BP reduc-
ions observed in this study were related to the dose of
liskiren, although the dose-response relationship was shal-
ow. A shallow dose-response is also generally observed with
ngiotensin-converting enzyme inhibitors and ARBs, and
as been attributed to inter-patient variability in responses
o renin system inhibition (14). It should be noted, however,
hat studies with ARBs have shown considerable differences
n the dose-response relationship among individual drugs of
hat class (15).
A high proportion of patients achieved a successful
reatment response with aliskiren (approximately 60% to
0% across the dose range). Treatment response was defined
s a reduction of msDBP from baseline to 90 mm Hg
i.e., goal attainment) or by 10 mm Hg. A 10-mm Hg
ifference in usual BP has been shown to be associated with
t least a 2-fold difference in the rate of death from stroke,
nd from ischemic heart disease and other vascular causes
16). More than a third of patients achieved BP control (BP
140/90 mm Hg) at the lowest dose and 46% achieved BP
ontrol at a dose of 600 mg/day.
In this study, the 600-mg dose of aliskiren caused
umerically larger BP reductions compared with the
00-mg dose (between-treatment difference in SBP/DBP
.1/1.4 mm Hg), but the differences were not statistically
Overall Incidence of AEs, Discontinuations Dueof Patients During the Double-Blind Treatment P
Table 2 Overall Incidence of AEs, Discontinof Patients During the Double-Blind
Plac
(n 
All-cause AEs 43
Treatment-related AEs 7
Discontinuation due to AEs 3
All-cause AEs occurring in 2% of patients
in any group
Headache 9
Nasopharyngitis 6
Diarrhea 1
Upper respiratory tract infection 4
Back pain 2
Dizziness 4
Nausea 2
Epistaxis 0
Constipation 0
Fatigue 0
Data are presented as the percentage of patients with at least 1 adver
groups.ignificant. A previous dose-finding study by Gradman et al. b7), which to date is the only other study to investigate the
ffects of aliskiren 600 mg in patients with hypertension,
howed that aliskiren 300 mg provided virtually the same
P reduction as aliskiren 600 mg. The balance of evidence,
herefore, suggests that aliskiren 600 mg does not offer a
ignificantly greater BP-lowering effect than aliskiren 300
g in patients with mild-to-moderate hypertension. The
agnitude of BP reductions with aliskiren was smaller in
he subset of black patients as compared with Caucasian
atients in the present study, although the direction and
attern of responses were similar in the 2 racial groups.
hese results are consistent with the well-documented finding
hat the antihypertensive efficacy of renin system blockade is
ower in black patients than in white patients (17,18).
Continuous, smooth BP lowering is important to
aximize the benefits of antihypertensive treatment and
revent the detrimental effects of variability of ambula-
ory BP (19). Furthermore, most individuals experience a
urge in BP in the early hours of the morning (20), the
ime when protection is extremely important (21,22). In
he present study, aliskiren provided effective, smooth
4-h BP control, with a trough-to-peak ratio for maDBP
f 64% for the 150-mg dose and in the range of 90% for
igher doses. This surpasses the trough-to-peak ratios of
ome commonly used antihypertensive drugs (23). Con-
istent with its long half-life, BP suppression with
liskiren administered at approximately 8 AM was main-
ained throughout the high-risk period in the early hours
f the following morning.
Aliskiren suppressed PRA, consistent with findings of
revious studies (9,24). Although RC was increased
uring aliskiren treatment, due to loss of feedback inhi-
s, and AEs Occurring in >2%(S fety Population, n  672)
ns Due to AEs, and AEs Occurring in >2%
tment Period (Safety Population, n  672)
Aliskiren
150 mg
(n  172)
300 mg
(n  169)
600 mg
(n  166)
40.1 46.7 52.4
2.3 9.5 12.0
0.6 1.8 1.2
7.0 7.7 5.4
2.9 3.6 1.8
1.2 1.8 11.4*
2.3 2.4 3.0
1.2 0.0 0.6
1.2 5.3 3.0
1.2 1.8 0.0
0.6 0.0 2.4
0.0 0.0 3.6
0.0 1.2 3.0
t (AE) in the respective category. *p 0.0001 versus other treatmentto AEeriod
uatio
Trea
ebo
165)
.0
.3
.6
.7
.1
.2
.2
.4
.2
.4
.6
.6
.6ition by angiotensin II on renin release, potent renin
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March 20, 2007:1157–63 Dose-Related BP Lowering by Aliskirennhibition by aliskiren maintained PRA at a level sub-
tantially below baseline.
A notable degree of BP reduction was maintained for at
east 2 weeks after treatment withdrawal, with no evidence
f rebound effects on BP, which can be a problem with some
ntihypertensive drugs (25,26). Sustained BP lowering co-
ncided with persistent PRA suppression. Sustained renin
ystem suppression and BP lowering may be clinically
eneficial, ensuring that BP control is maintained in those
nstances when patients inadvertently miss a dose.
Aliskiren treatment was well tolerated, the incidence of
Es being comparable with placebo at doses of 300 mg and
elow. The placebo-like tolerability of aliskiren at doses up
o and including 300 mg is consistent with the findings of
radman et al. (7). An increased incidence of diarrhea was
een with the highest dose of aliskiren (600 mg); the
echanism by which diarrhea was induced is not clear, and
t did not occur with aliskiren 150 and 300 mg. This did not
ffect persistence on study treatment; few patients discon-
inued from the treatment period due to any AE. Due to the
inimal incremental BP reduction and increased incidence
f diarrhea with the 600-mg dose relative to the 300-mg
ose, the clinical dose range for aliskiren for the treatment
f hypertension is expected to include only the 150 and 300
g doses.
onclusions
his study found that aliskiren, 150 to 600 mg once daily,
rovides significant antihypertensive efficacy in patients
ith mild-to-moderate hypertension. Dosages up to and
ncluding 300 mg had placebo-like tolerability; the 600-mg
ose raised no safety concerns, but was associated with
iarrhea in about 11% of patients. Blood pressure reduction
as sustained throughout the 24-h dosing period. Blood
ressure-lowering effects gradually diminished after treat-
ent withdrawal, but did not return to baseline by the end
f 2 weeks.
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